NASDAQ:NRBO NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis $4.15 +0.06 (+1.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.06▼$4.2650-Day Range$3.81▼$5.0052-Week Range$2.90▼$6.75Volume14,553 shsAverage Volume615,435 shsMarket Capitalization$20.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get NeuroBo Pharmaceuticals alerts: Email Address NeuroBo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.0% Upside$10.00 Price TargetShort InterestHealthy16.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingAcquiring Shares$7.96 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($4.89) to ($2.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.94 out of 5 starsMedical Sector422nd out of 936 stocksPharmaceutical Preparations Industry192nd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNeuroBo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeuroBo Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about NeuroBo Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted16.20% of the float of NeuroBo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNeuroBo Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuroBo Pharmaceuticals has recently decreased by 43.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuroBo Pharmaceuticals does not currently pay a dividend.Dividend GrowthNeuroBo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRBO. Previous Next 3.0 News and Social Media Coverage News SentimentNeuroBo Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NeuroBo Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NRBO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuroBo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,964,379.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.54% of the stock of NeuroBo Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.37% of the stock of NeuroBo Pharmaceuticals is held by institutions.Read more about NeuroBo Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeuroBo Pharmaceuticals are expected to grow in the coming year, from ($4.89) to ($2.28) per share.Price to Book Value per Share RatioNeuroBo Pharmaceuticals has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeuroBo Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More NRBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRBO Stock News HeadlinesJune 26, 2024 | insidertrades.comNeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Major Shareholder St Co. Ltd Dong-A Acquires 2,544,530 SharesJuly 11, 2024 | prnewswire.comNeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in JulyJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.June 30, 2024 | 247wallst.comHuge Insider Buying at a Warren Buffett Pick and 5 Other StocksJune 26, 2024 | prnewswire.comNeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityJune 25, 2024 | prnewswire.comNeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 24, 2024 | prnewswire.comNeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 22, 2024 | prnewswire.comNeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 28, 2024 | finance.yahoo.comNRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024May 22, 2024 | markets.businessinsider.comNeuroBo Pharma Reveals Positive Pre-clinical Data For DA -1241 In Combination In Liver FibrosisMay 22, 2024 | msn.comNeuroBo says DA-1241, Wegovy combo shows potential in treating MASHMay 22, 2024 | msn.comNeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis SuccessMay 22, 2024 | prnewswire.comNeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneMay 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug DevelopmentsMay 9, 2024 | msn.comMaxim Group Initiates Coverage of NeuroBo Pharmaceuticals (NRBO) with Buy RecommendationMay 9, 2024 | investorplace.comNRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024See More Headlines Receive NRBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRBO CUSIPN/A CIK1638287 Webwww.neurobopharma.com Phone(857) 702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+136.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.22% Return on Assets-69.52% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book1.23Miscellaneous Outstanding Shares4,910,000Free Float4,880,000Market Cap$20.77 million OptionableNot Optionable Beta-0.27 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Hyung-Heon Kim (Age 49)CEO, President, Principal Executive & Director Comp: $625.16kMr. Marshall H. Woodworth (Age 66)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $154.5kDr. Mi-Kyung KimChief Scientific OfficerMr. Robert HomolkaSenior Vice President of Clinical OperationsKey CompetitorsBenitec BiopharmaNASDAQ:BNTCSCYNEXISNASDAQ:SCYXLifeVantageNASDAQ:LFVNAssembly BiosciencesNASDAQ:ASMBPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsidersSt Co. Ltd Dong-ABought 2,544,530 shares on 6/23/2024Total: $7.96 M ($3.13/share)View All Insider Transactions NRBO Stock Analysis - Frequently Asked Questions How have NRBO shares performed this year? NeuroBo Pharmaceuticals' stock was trading at $3.70 at the start of the year. Since then, NRBO stock has increased by 12.2% and is now trading at $4.15. View the best growth stocks for 2024 here. How were NeuroBo Pharmaceuticals' earnings last quarter? NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.37. When did NeuroBo Pharmaceuticals' stock split? Shares of NeuroBo Pharmaceuticals reverse split on the morning of Thursday, December 21st 2023. The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of NeuroBo Pharmaceuticals? Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NeuroBo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN). This page (NASDAQ:NRBO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.